Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Patent
1995-06-06
1996-06-04
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
422 44, 210504, 210509, 604 4, 604 5, 604 6, A61K 3514, A61M 114, A61M 3700
Patent
active
055230962
ABSTRACT:
This invention provides a composition, device and method for the removal of selected factors, such as cytokines or pharmaceuticals, from a substance such as whole blood or plasma. Advantageously, the invention provides for the treatment or prevention of septic shock syndrome or other conditions evidenced by the presence of cytokines in a patient by contacting the patient's whole blood with a composition comprising silica and a surface treatment material, such as heparin, but preferably human serum albumin (HSA). The treatment lowers the cytokine concentration of the blood. Pharmaceuticals can be removed from an individual's whole blood or plasma, such as for use in treating drug overdosage.
REFERENCES:
patent: 3607857 (1971-09-01), Nelson
patent: 3998946 (1976-12-01), Condie
patent: 4006059 (1977-02-01), Butler
patent: 4059685 (1977-11-01), Johnson
patent: 4072566 (1978-02-01), Lynn
patent: 4102746 (1978-07-01), Goldberg
patent: 4420395 (1983-12-01), Tanihara et al.
patent: 4472303 (1984-09-01), Tanihara
patent: 4728432 (1988-03-01), Sugiyama
patent: 4748121 (1988-05-01), Beaver et al.
patent: 4787974 (1988-11-01), Ambrus
patent: 4861707 (1989-08-01), Balint, Jr. et al.
patent: 4865841 (1989-09-01), Balint, Jr.
patent: 4883765 (1989-11-01), Tamir
patent: 4963265 (1990-10-01), Okarma
patent: 5022988 (1991-06-01), Okarma
patent: 5041079 (1991-08-01), Takashima
patent: 5294401 (1994-03-01), Hagiwara et al.
patent: 5421815 (1995-06-01), Noguchi et al.
patent: 5437861 (1995-08-01), Okarma et al.
Lee et al., "Hemofiltration Removes Toxic Mediators and Prolongs Survival in Staphylococcus aureus Sepsis Acute Lung Injury" Am. Rev. Respir. Dis. (1990) 141:A140. An abstract of the conference paper presented on May 20-24, 1990, at the World Conference on Lung Health, Boston, MA, is enclosed herewith.
Bol'shakov et al., "Protective Effect of Anti-staphylococcal Immunosorbent on the Phenotype of Lymphocyte Membrane in Diffuse Staphylococcus-Pseudomonas Peritonitis" Vestn. Akad. Med. Nauk. SSSR (1991) 7:36-40. An English abstract is enclosed herewith.
Lin et al., "Laboratory Evaluation of a Hemoperfusion Adsorptive Resin Column for the Treatment of Sepsis and Septic Shock" Abstract submitted to American Society for Apheresis, 13th Annual Meeting, (1992), (1 p. total).
Matson et al., "Continuous Arteriovenous Hemofiltration (CAVH) Therapy for Sepsis-induced Acute Lung Injury in Immature Swine" FASEB J. (1990) 4(4):A953. An abstract of the conference paper presented on Apr. 1-5, 1990, at the 74th Annual Meeting of the Federation of American Societies for Experimental Biology, Washington, D.C., is enclosed herewith.
Mollnes et al., "Formation of C5a During Cardiopulmonary Bypass: Inhibition by Precoating with Heparin" Ann. Thorac. Surg. (1991) 52:92-97.
Murugavel, S., "In Vitro Studies of the Efficacy of Reversed Phase Silica Gel as a Sorbent for Hemo- and Plasmaperfusion" J. Toxicol. Clin. Toxicol. (1992) 30(1):69-82. An English abstract is enclosed herewith.
Tamiya et al., "Significance of the Concentrated Red Cell and Albumin Priming Method with Particular Reference to Anaphylatoxin Generation" J. Thoracic & Cardiovascular Surg. (1992) 103(1):78-86.
Blankenship John
Elkalay Mohammad A.
Lin Abraham T.
Okarma Thomas B.
Applied Immune Sciences, Inc.
Kulkosky Peter F.
Page Thurman K.
LandOfFree
Removal of selected factors from whole blood or its components does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Removal of selected factors from whole blood or its components, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Removal of selected factors from whole blood or its components will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-381802